Telesis Bio, Inc. (TBIO)
NASDAQ: TBIO · IEX Real-Time Price · USD
0.321
0.00 (0.03%)
At close: Apr 25, 2024, 4:00 PM
0.318
-0.004 (-1.21%)
After-hours: Apr 25, 2024, 7:58 PM EDT
Telesis Bio Market Cap
Telesis Bio has a market cap or net worth of $9.68 million as of April 26, 2024. Its market cap has decreased by -89.04% in one year.
Market Cap
9.68M
Enterprise Value
24.72M
1-Year Change
-89.04%
Ranking
Category
Stock Price
$0.32
Market Cap Chart
Since the IPO on June 18, 2021, Telesis Bio's market cap has decreased from $451.66M to $9.68M, a decrease of -97.86%. That is a compound annual growth rate of -74.01%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Apr 24, 2024 | 9.60M | -1.03% |
Apr 23, 2024 | 9.70M | 3.19% |
Apr 22, 2024 | 9.40M | 1.08% |
Apr 19, 2024 | 9.30M | -6.06% |
Apr 18, 2024 | 9.90M | -13.16% |
Apr 17, 2024 | 11.40M | 3.64% |
Apr 16, 2024 | 11.00M | -2.65% |
Apr 15, 2024 | 11.30M | -8.13% |
Apr 12, 2024 | 12.30M | -6.11% |
Apr 11, 2024 | 13.10M | 2.34% |
Apr 10, 2024 | 12.80M | -0.78% |
Apr 9, 2024 | 12.90M | - |
Apr 8, 2024 | 12.90M | -2.27% |
Apr 5, 2024 | 13.20M | -4.35% |
Apr 4, 2024 | 13.80M | -3.50% |
Apr 3, 2024 | 14.30M | 8.33% |
Apr 2, 2024 | 13.20M | 0.76% |
Apr 1, 2024 | 13.10M | -0.76% |
Mar 28, 2024 | 13.20M | -2.22% |
Mar 27, 2024 | 13.50M | 3.05% |
Mar 26, 2024 | 13.10M | -2.96% |
Mar 25, 2024 | 13.50M | 1.50% |
Mar 22, 2024 | 13.30M | -5.00% |
Mar 21, 2024 | 14.00M | 2.94% |
Mar 20, 2024 | 13.60M | -16.05% |
View and export this data all the way back to 2021.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Inhibikase Therapeutics | 10.23M |
BioCardia | 10.10M |
Organovo Holdings | 10.04M |
Bionomics | 9.87M |
Novo Integrated Sciences | 9.81M |
Aeterna Zentaris | 9.57M |
Fresh2 Group | 9.54M |
Chemomab Therapeutics | 9.52M |